Mid-Morning Market Update: Markets Mixed; Kroger Tops Q2 Views
Following the market opening Friday, the Dow traded down 0.15% to 34,827.04 while the NASDAQ rose 0.32% to 15,296.61. The S&P also rose, gaining 0.03% to 4,494.53.
Roth Capital Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $46
Roth Capital analyst Elemer Piros maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $80 to $46.
Benzinga Pro’s Top 5 Stocks To Watch For Friday, Sept. 10, 2021: FCEL, AFRM, TTOO, APLS, ENDP
Today's 5 Stock Ideas:
FuelCell Energy (FCEL) - FuelCell Energy reports Q3 earnings results on Tuesday, September 14th.
Affirm (AFRM) - Shares up ~23% premarket. The company reported
Credit Suisse Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $38
Credit Suisse analyst Tiago Fauth maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and lowers the price target from $50 to $38.
10 Biggest Price Target Changes For Friday
Wells Fargo lowered the price target on General Motors Company (NYSE: GM) from $67 to $63. GM shares rose 0.7% to $48.78 in pre-market trading.
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 9)
Wedbush Downgrades Apellis Pharmaceuticals to Neutral, Lowers Price Target to $39
Wedbush analyst Laura Chico downgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Outperform to Neutral and lowers the price target from $71 to $39.
BMO Capital Maintains Outperform on Apellis Pharmaceuticals, Lowers Price Target to $69
BMO Capital analyst Matthew Luchini maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and lowers the price target from $89 to $69.
20 Stocks Moving in Friday’s Pre-Market Session
Gainers
IVERIC bio, Inc. (NASDAQ: ISEE) rose 29.6% to $11.26 in pre-market trading. Iveric Bio recently reported inducement grants under Nasdaq Listing Rule 5635(c)(4).